Effect of candesartan on coronary flow reserve in patients with systemic hypertension

Journal of Hypertension

Volumn 24, Issue 10, 2006, Pages 2109-2114

  Tomás, Juán Pablo ^a   Moya, José Luis ^a   Barrios, Vivencio ^a   Campuzano, Raquel ^b   Guzman, Gabriela ^a   Megías, Alicia ^a   Ruiz Leria, Soledad ^a   Catalán, Paz ^a   Marfil, Teresa ^a   Tarancón, Belén ^a   Muriel, Alfonso ^a   García Lledó, Alberto ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Guadalajara Hospital   (Spain)

Author keywords

Coronary flow reserve; Hypertension; Microcirculation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; VASCULAR PATENCY;

EID: 33748539361     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000244962.77609.57     Document Type: Article

References (39)

1. Thom S. Arterial structural modifications in hypertension. Effects of treatment. Eur Heart J 1997; 18 (Suppl E):E2-E4.
2. Takiuchi S, Rakugi H, Fujii H, Kamide K, Horio T, Nakatani S, et al. Carotid intima-media thickness is correlated with impairment of coronary flow reserve in hypertensive patients without coronary artery disease. Hypertens Res 2003; 26:945-951.
3. Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990; 15:43-51.
4. Britten MB, Zeiher AM, Schachinger V. Microvascular dysfunction in angiographically normal or mildly diseased coronary arteries predicts adverse cardiovascular long-term outcome. Coron Artery Dis 2004; 15:259-264.
5. Hamasaki S, Al Suwaidi J, Higano ST, Miyauchi K, Holmes DR Jr, Lerman A. Attenuated coronary flow reserve and vascular remodelling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol 2000; 35:1654-1660.
6. Galderisi M, Cicala S, Caso P, De Simone L, D'Errico A, Petrocelli A, et al. Coronary flow reserve and myocardial diastolic dysfunction in arterial systemic hypertension. Am J Cardiol 2002; 90:860-864.
7. Galderisi M, Caso P, Cicala S, De Simone L, Barbieri M, Vitale G, et al. Positive association between circulating free IGF-1 and coronary flow reserve in arterial systemic hypertension. Am J Hypertens 2002; 15:766-772.
8. Galderisi M, de Simone G, Cicala S, Caso P, De Simone L, D'Errico A, et al. Coronary flow reserve in hypertensive patients with appropriate and inappropriate left ventricular mass. J Hypertens 2003; 21:1-6.
9. Lahera V, Heras N, Sanz-Rosa D, Miana M, Cediel E, Davel AP, et al. Bloqueo del sistema renina-angiotensina y protección vascular antiaterosclerótica. Hipertensión 2004; 21:33-40.
10. Motz W, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 1996; 27:1031-1038.
11. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36:220-225.
12. Unger T. Differences among angiotensin II type I receptor blockers: characteristics of candesartan cilexetil. Blood Press 2000; 1:14-18.
13. Devereux RD. Detection of left ventricular hypertrophy by M-mode echocardiography: anatomic validation, standardization, and comparison to other methods. Hypertension 1987; 9:II-19-II-26.
14. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall. A direct measurement with ultrasound imaging. Circulation 1986; 74:1399-1406.
15. Salonen R, Salonen JT. Determinants of carotid intima-media thickness: a population-based ultrasonography study in eastern Finnish men. J Intern Med 1991; 229:225-231.
16. Brilla CJ, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial arteries. Circ Res 1991; 69:107-115.
17. Chilian WU, with contributions from the NHLBI Workshop Participants. Coronary microcirculation in health and disease: summary of an NHLBI workshop. Circulation 1997; 95:522-528.
18. Opherk D, Mall G, Zebe H, Schwarz F, Weihe E, Manthey J, Kubler W. Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation 1984; 69:1-7.
19. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
20. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993; 88:993-1003.
21. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension 2001; 37:1047-1052.
22. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25:474-481.
23. Buus NH, Bottcher M, Jorgensen CG, Christensen KL, Thygesen K, Nielsen TT, Mulvany NJ. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension 2004; 44:465-470.
24. Parodi O, Neglia D, Palombo C, Sambuceti G, Giorgetti A, Marabotti C. Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation 1997; 96:864-873.
25. Schiffrin EL, Park JB, Intentan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin antagonist losartan. Circulation 2000; 101:1653-1659.
26. Schiffrin EL, Park JB, Pu K. Effect of crossing over hypertensive patients from a beta-blocker to a angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002; 20:70-78.
27. Schiffrin EL. Effect of antihypertensive treatment on small artery remodelling in hypertension. Can J Physiol Pharmacol 2003; 81:168-176.
28. Park JB, Schiffrin El.. Small artery remodelling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19:921-930.
29. Akinboboye OO, Chou RL, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. J Am Coll Cardiol 2002; 40:703-709.
30. Barrios V, Calderón A, Tomás JP, Ruiz S, Moya JL, Megias A, et al. Echocardiographic left ventricular hypertrophy regression induced by candesartan in clinical practice. The VIPE study. J Hypertens 2005; 23 (Suppl 2):S39.
31. Antony J, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94:3115-3122.
32. Motz W, Vogt M, Scheler S, Schwartzkopff B, Strauer BE. Verbesserung der Koronarreserve nach Hypertrophieregression durch antihypertensive Therapie mit einem Beta-Rezeptorblocker. Dtsch Med Wochenschr 1993; 118:535-540.
33. Marceau M, Kouame N, Lacourciere Y, Cleroux J. Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy. J Hypertens 1998; 16:673-679.
34. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994; 23:83-91.
35. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287:H435-H446.
36. 2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 2001; 14:98S-102S.
37. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651-657.
38. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004; 109:2296-2301.
39. Unger T. Differences among angiotensin II type I receptor blockers: characteristics of candesartan cilexetil. Blood Press 2000; 1:14-18.